Okamura Nobuyuki, Harada Ryuichi, Furumoto Shozo, Arai Hiroyuki, Yanai Kazuhiko, Kudo Yukitsuka
Department of Pharmacology, Tohoku University School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, 9808575, Japan,
Curr Neurol Neurosci Rep. 2014 Nov;14(11):500. doi: 10.1007/s11910-014-0500-6.
In several neurodegenerative diseases that are collectively called tauopathies, progressive accumulation of tau in the brain is closely associated with neurodegeneration and cognitive impairment. Noninvasive detection of tau protein deposits in the brain would be useful to diagnose tauopathies as well as to track and predict disease progression. Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo. For use of tau PET as a biomarker of tau pathology in Alzheimer's disease, PET tracers should have high affinity to PHF-tau and high selectivity for tau over amyloid-β and other protein deposits. PET tau imaging enables the longitudinal assessment of the spatial pattern of tau deposition and its relation to amyloid-β pathology and neurodegeneration. This technology could also be applied to the pharmacological assessment of anti-tau therapy, thereby allowing preventive interventions.
在几种统称为tau蛋白病的神经退行性疾病中，tau蛋白在大脑中的逐渐积累与神经退行性变和认知障碍密切相关。大脑中tau蛋白沉积的无创检测对于诊断tau蛋白病以及追踪和预测疾病进展将是有用的。最近，包括T807、THK-5117和PBB3在内的几种tau正电子发射断层显像（PET）示踪剂已被开发出来，并成功地在体内对神经原纤维病变进行成像。为了将tau PET用作阿尔茨海默病中tau蛋白病变的生物标志物，PET示踪剂应与磷酸化tau蛋白（PHF-tau）具有高亲和力，并且对tau蛋白的选择性高于淀粉样β蛋白和其他蛋白质沉积物。PET tau成像能够纵向评估tau蛋白沉积的空间模式及其与淀粉样β蛋白病变和神经退行性变的关系。这项技术还可应用于抗tau治疗的药理学评估，从而实现预防性干预。
